Gamida Cell Ltd (NASDAQ:GMDA) Expected to Announce Earnings of -$0.37 Per Share
Equities analysts expect Gamida Cell Ltd (NASDAQ:GMDA) to post earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Gamida Cell’s earnings. Gamida Cell reported earnings per share of ($14.23) during the same quarter last year, which suggests a positive year over year growth rate of 97.4%. The business is expected to report its next earnings results on Friday, February 14th.
On average, analysts expect that Gamida Cell will report full-year earnings of ($1.16) per share for the current fiscal year. For the next year, analysts forecast that the business will post earnings of ($1.31) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Gamida Cell.
Gamida Cell (NASDAQ:GMDA) last released its earnings results on Tuesday, August 6th. The company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.32).
Shares of Gamida Cell stock traded down $0.13 on Wednesday, reaching $3.01. 100 shares of the stock were exchanged, compared to its average volume of 21,977. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.23. Gamida Cell has a twelve month low of $2.97 and a twelve month high of $15.41. The firm has a market capitalization of $78.72 million and a price-to-earnings ratio of -0.29. The business has a 50 day moving average price of $4.21 and a two-hundred day moving average price of $8.45.
A number of hedge funds have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. purchased a new position in Gamida Cell during the first quarter valued at approximately $53,000. Norges Bank purchased a new position in Gamida Cell during the fourth quarter valued at approximately $88,000. Royal Bank of Canada purchased a new position in Gamida Cell during the second quarter valued at approximately $71,000. Millennium Management LLC purchased a new position in Gamida Cell during the fourth quarter valued at approximately $210,000. Finally, Bank Hapoalim BM purchased a new position in Gamida Cell during the second quarter valued at approximately $195,000. Institutional investors own 13.25% of the company’s stock.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Recommended Story: How to Track your Portfolio in Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.